Profusa (NASDAQ:PFSA) Lowered to “Strong Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Profusa (NASDAQ:PFSA) to a strong sell rating in a research note published on Saturday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

Profusa Price Performance

PFSA stock opened at $2.01 on Friday. Profusa has a 1 year low of $1.88 and a 1 year high of $180.00. The company has a market capitalization of $2.47 million, a PE ratio of -0.90 and a beta of -0.14. The company has a fifty day moving average of $7.33.

Profusa (NASDAQ:PFSA) last released its quarterly earnings results on Wednesday, November 19th. The company reported ($52.50) EPS for the quarter.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.